LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) will engage investors next week as members of its management team participate in one-on-one meetings and fireside chats at two high-profile healthcare conferences.
Executives will present at the Piper Sandler 37th Annual Healthcare Conference on December 2 at 2:30 p.m. ET, followed by a fireside chat at the Evercore ISI 8th Annual Healthcare Conference on December 4 at 10:00 a.m. ET. Both events will be streamed live, with replays available for 90 days on the company’s website under “Events & Presentations.”
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead candidate, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis, a debilitating and ultra-rare lung condition. The therapy is administered through a proprietary eFlow nebulizer system developed by PARI Pharma for targeted inhalation.
The company said its leadership team brings deep expertise in rare respiratory conditions and pulmonary care, with a track record of advancing complex therapies from development through potential commercialization. The upcoming conferences will give investors insight into Savara’s progress, clinical strategy and expectations as it advances MOLBREEVI through late-stage trials.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.